New hyperprolactinemia and anovulation model in common marmoset (Callithrix jacchus) and effect of cabergoline

European Journal of Pharmacology

Volumn 368, Issue 1, 1999, Pages 57-66

  Moro, Makoto ^a   Inada, Yoichi ^a   Kojima, Masami ^a   Miyata, Hiroshi ^a   Komatsu, Hidetada ^a   Torii, Ryuzo ^b  

^a Kissei Pharmaceutical K   (Japan)

^b SHIGA UNIVERSITY OF MEDICAL SCIENCE   (Japan)

Author keywords

Anovulation; Cabergoline; Common marmoset; Dopamine D2 receptor agonist; Hyperprolactinemia; Laparoscopy

Indexed keywords

BROMOCRIPTINE; CABERGOLINE; ESTRADIOL; PROGESTERONE; PROLACTIN; SULPIRIDE;

ANIMAL MODEL; ANIMAL TISSUE; ANOVULATION; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; ESTRADIOL BLOOD LEVEL; FEMALE; HYPERPROLACTINEMIA; MARMOSET; NONHUMAN; ORAL DRUG ADMINISTRATION; OVARY CYCLE; PRIORITY JOURNAL; PROGESTERONE BLOOD LEVEL; PROLACTIN BLOOD LEVEL;

ANIMALS; ANOVULATION; BROMOCRIPTINE; CALLITHRIX; DISEASE MODELS, ANIMAL; DOPAMINE AGONISTS; DOPAMINE ANTAGONISTS; ERGOLINES; ESTRADIOL; FEMALE; HYPERPROLACTINEMIA; MENSTRUAL CYCLE; PROGESTERONE; PROLACTIN; SULPIRIDE; TIME FACTORS;

EID: 0032970446     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(98)00940-6     Document Type: Article

References (35)

1. Aono T., Shioji T., Kinugawa T., Onishi T., Kurachi K. Clinical and endocrinological analyses of patients with galactorrhea and menstrual disorders due to sulpiride or metoclopramide. J. Clin. Endocrinol. Metab. 47:1978;675-680.
2. Aso T., Matsuoka M., Su J., Horie K., Taii S., Motohashi T., Nishimura T. Influence of sulpiride-induced hyperprolactinemia on baboon menstrual cycle: a longitudinal study. J. Med. Primatol. 11:1982;20-34.
3. Barrow D.L., Tindall G.T., Kovacs K., Thorner M.O., Horvath E., Hoffman J.C. Jr. Clinical and pathological effects of bromocriptine on prolactin-secreting and other pituitary tumors. J. Neurosurg. 60:1984;1-7.
4. Besser G.M., Parke L., Edwards C.R.W., Forsyth I.A., MacNeilly A.S. Galactorrhea: successful treatment with reduction of plasma prolactin levels. Br. Med. J. 3:1972;669-672.
5. Bevan J.S., Webster J., Burke C.W., Scanlon M.F. Dopamine agonists and pituitary tumor shrinkage. Endocr. Rev. 13:1992;220-240.
6. Biller B.M.K., Molitch M.E., Vance M.L., Cannistraro K.B., Davis K.R., Simons J.A., Klibanski A. Treatment of prolactin-secreting macroadenomas with the once-weekly dopamine agonist cabergoline. J. Clin. Endocrinol. Metab. 81:1996;2338-2343.
7. Ciccarelli E., Giusti M., Miola C., Potenzoni F., Sghedoni D., Camanni F., Giordano G. Effectiveness and tolerability of long-term treatment with cabergoline, a new long-lasting ergoline derivative, in hyperprolactinemic patients. J. Clin. Endocrinol. Metab. 69:1989;725-728.
8. Cooper, P.R., 1991. Nonoperative management of prolactinomas. In: Cooper, P.R. (Ed.), Contemporary Diagnosis and Management of Pituitary Adenomas. AANS Publications Committee, IL, pp. 83-100.
9. Crosignani P.G., Ferrari C. Dopaminergic treatments for hyperprolactinemia. Clin. Obstet. Gynecol. 4:1990;441-455.
10. Dall'Ara A., Lima L., Cocchi D., Di Salle E., Cancio E., Devesa J., Müller E.E. Inhibitory effect of cabergoline on development of estrogen-induced prolactin-secreting adenomas of the pituitary. Eur. J. Pharmacol. 151:1988;97-102.
11. Di Salle E., Ornati G., Briatico G. FCE 21336, a new ergoline derivative with a potent and long-acting lowering effect on prolactin secretion in rats. J. Endocrinol. Invest. 5(Suppl. 1):1982;45. Abstract.
12. Di Salle E., Ornati G., Giudici D., Ragazzi P., Briatico G. Effect of the new ergoline derivative FCE 21336 on prolactin and LH secretion in the rats. J. Endocrinol. Invest. 6(Suppl. 1):1983;6. Abstract.
13. Di Salle E., Ornati G., Giudici D. A comparison of the in vivo and in vitro duration of prolactin lowering effect in rats of FCE 21336, pergolide and bromocriptine. J. Endocrinol. Invest. 7(Suppl. 1):1984;32. Abstract.
14. Eguchi K., Kawamoto K., Uozumi T., Ito A., Arita K., Kurisu K. In vivo effect of cabergoline, a dopamine agonist, on estrogen-induced rat pituitary tumors. Endocr. J. 42:1995;153-161.
15. Enjalbert A., Backaert J. Pharmacological characterization of the D2 dopamine receptor negatively coupled with adenylate cyclase in rat anterior pituitary. Mol. Pharmacol. 23:1983;576-584.
16. Ferrari C., Crosignani P.G. Review: Medical treatment of hyperprolactinemic disorders. Hum. Reprod. 1:1986;507-514.
17. Ferrari C., Barbieri C., Caldara R., Mucci M., Codecasa F., Paracchi A., Romano C., Boghen M., Dubini A. Long-lasting prolactin-lowering effect of cabergoline, a new dopamine agonist, in hyperprolactinemic patients. J. Clin. Endocrinol. Metab. 63:1986;941-945.
18. Ferrari C., Mattei A., Melis G.B., Paracchi A., Muratori M., Faglia G., Sghedoni D., Crosignani P.G. Cabergoline: long-acting oral treatment of hyperprolactinemic disorders. J. Clin. Endocrinol. Metab. 68:1989;1201-1206.
19. Ferrari C., Paracchi A., Mattei A.M., de Vincentiis S., D'Alberton A., Crosignani P.G. Cabergoline in the long-term therapy of hyperprolactinemic disorders. Acta Endocrinol. 126:1992;489-494.
20. Ho K.I., Thorner M.O. Therapeutic applications of bromocriptine in endocrine and neurological diseases. Drugs. 36:1988;67-82.
21. Kholkute S.D., Patil R.P., Desai M.P., Puri C.P. Metachlopromide-induced hyperprolactinemia fails to affect ovarian cyclicity in common marmosets (Callithrix jacchus). Primates. 29:1988;549-555.
22. Kinukawa M., Moro M., Kojima M. Effect of cabergoline on hyperprolactinemic model in rats. Clin. Rep. 30:1996;2525-2530.
23. Lloyd H.M., Meares J.D., Jacobi J. Effects of oestrogen and bromocriptine on in vivo secretion and mitosis in prolactin cells. Nature. 255:1975;497-498.
24. MacLeod R.M., Lobyn C. Mechanism of increased prolactin secretion by sulpiride. J. Endocrinol. 72:1977;273-277.
25. Mancini A.M., Guitelman A., Vargas C.A., Debeljuk L., Aparicio N.J. Effect of sulpiride on serum prolactin levels in humans. J. Clin. Endocrinol. Metab. 42:1976;181-184.
26. Mattei A.M., Ferrari C., Baroldi P., Cabioni V., Paracchi A., Galparoli C., Romano C., Spellechia D., Gerevini G., Crosignani P.G. Prolactin-lowering effect of acute and once weekly repetitive oral administration of cabergoline at two dose levels in hyperprolactinemic patients. J. Clin. Endocrinol. Metab. 66:1988;193-198.
27. Molitch M.E. Management of prolactinomas. Annu. Rev. Med. 41:1989;255.
28. Moro M., Torii R., Koizumi H., Inada Y., Etoh Y., Miyata H., Tanioka Y. Serum levels of prolactin during the ovarian cycle, pregnancy, and lactation in the common marmoset (Callithrix jacchus). Primates. 36:1995;249-257.
29. Oseko F., Morikawa K., Motohashi T., Aso T. Effects of chronic sulpiride-induced hyperprolactinemia on menstrual cycles of normal women. Obstet. Gynecol. 72:1988;267-271.
30. Philosophe R., Seibel M.M. Novel approaches to the management of hyperprolactinemia. Curr. Opin. Obstet. Gynecol. 3:1991;336-342.
31. Robert E., Musatti L., Piscitelli G., Ferrari C. Pregnancy outcome after treatment with the ergot derivative, cabergoline. Reprod. Toxicol. 10:1996;333-337.
32. Tallo D., Malarkey W.B. Adrenergic and dopaminergic modulation of growth hormone and prolactin secretion in normal and tumor-bearing human pituitaries in monolayer culture. J. Clin. Endocrinol. Metab. 53:1981;1278-1284.
33. Torii R., Abbott D.H., Nigi H. Morphological changes of the ovary and hormonal changes through the ovarian cycle of the common marmoset (Callithrix jacchus). Primates. 37:1996;49-56.
34. Vance M.L., Evans W.S., Thorner M.O. Drugs five years later: bromocriptine. Ann. Int. Med. 100:1984;78-91.
35. Webster J., Piscitelli G., Polli A., Ferrari C., Ismail I., Scanlon M.F. A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea. New Engl. J. Med. 331:1994;904-909.